



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gregory Burrows; Arthur A. Vandenbark

Title: Recombinant MHC Molecules Useful For
Manipulation of Antigen-Specific T-Cells

Serial No.: 09/847,172

Filing Date: May 1, 2001


Examiner/Unit: F. P. Vandervegt

Attorney Docket No.: OHSU-1-0301 (Formerly 2357-003-03)

TRANSMITTAL LETTER

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited in the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 11th day of January, 2006.


Susan M. Wanger

COMMISSIONER FOR PATENTS:

Transmitted herewith is:

1. A response and Amendment/Response in the above-identified application.
2. No additional claim fees are required.
6. Return postcard.

Respectfully submitted,

BLACK LOWE & GRAHAM PLLC


Jeffrey J. King
Registration No. 38,515
701 Fifth Avenue – Suite 4800
Seattle, WA 98104
Telephone: (206) 381-3300
Facsimile: (206) 381-3301



DOCKET NO. OHSU-1-0301 (Formerly 2357-003-03)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Gregory G. Burrows Confirmation No.: 5303

Serial No.: 09/847,172

Group Art Unit: 1644

Filing Date: May 1, 2001


Examiner: Francois P. Vandervegt

Title: Recombinant MHC Molecules Useful For Manipulation of Antigen-Specific T-Cells

Attorney Docket No.: OHSU-1-0301 (Formerly 2357-003-03)

CERTIFICATE OF MAILING

I certify that this communication, and any document being attached hereto, are being deposited with the U.S. Postal Service with sufficient postage as First Class Mail addressed to: The Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 this 11th day of January 2006.



Susan M. Wanger

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION

TO THE COMMISSIONER FOR PATENTS:

In response to the Final Office Action mailed October 11, 2005, Applicants respectfully request reconsideration of the application in view of the following amendments and remarks.

Amendments to and a current listing of the claims begin on page 2 of this paper.

Remarks begin on page 6 of this paper.